Canakinumab
Interleukin Inhibitors
Sold as ILARIS
- Drug class
- Interleukin Inhibitors
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 4
Overview
Canakinumab is an active pharmaceutical ingredient in the Interleukin Inhibitors group (L04AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 22, 2026 |
| EU European Union | EMA | 1 | May 5, 2026 |
| CA Canada | Health Canada | 1 | October 21, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: • Muckle-Wells syndrome (MWS), • Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), • Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).
EUEuropean Union· EMA
1 product
Uses
Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: • Muckle-Wells syndrome (MWS), • Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), • Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). 3 Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).
CACanada· Health Canada
1 product
Uses
ILARIS® (canakinumab) is an interleukin-1 beta (IL-1β) inhibitor indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes. Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the ongoing management of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years and older, including: Familial Cold Autoinflammatory Syndrome (FCAS)/ Familial Cold Urticaria (FCU), Muckle-Wells Syndrome (MWS) ILARIS may also be used in Neonatal-Onset Multisystem Inflammatory Disease (NOMID)/ Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA).
Clinical data have not confirmed improvement in CNS symptoms in patients with this phenotype. Tumor Necrosis Factor receptor Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients. Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients.
Drug interactions
Known interactions involving Canakinumab. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 263. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011093 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/001109 · revised May 5, 2026
- [3]Health Canada (DPD) · 02460351 · revised October 21, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.